Financial News

Aimmune Therapeutics soars on DBV Technologies' disappointing results

Shares of Aimmune Therapeutics Inc. (Nasdaq: AIMT) surged $7.28 to close at $32.94 after rival DBV Technologies (Nasdaq: DBVT) reported disappointing results from a Phase 3 study of the peanut allergy treatment AR101. DBV Technologies stock collapsed $19.75 to close at $28.32.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback